

**Amended Annex 1**

**EP (UK) 1 641 822**

**Existing claims 1 – 26 are to be deleted.**

- ~~271.~~ An isolated antibody which specifically binds to ~~the~~ an isolated IL-17A/F heterodimeric complex according to Claim 23 or Claim 24 and which inhibits the activity of the IL-17A/F heterodimeric complex to induce production of IL-8 and IL-6, wherein the isolated IL-17A/F heterodimeric complex comprises SEQ ID NO:3 and SEQ ID NO:4, without their associated signal peptides, and further comprises two interchain disulfide linkages between SEQ ID NO:3 and SEQ ID NO:4; and wherein the antibody is either human or humanized.
- ~~2.~~ The isolated antibody of Claim 1, wherein said antibody has a Kd for the IL-17A/F heterodimeric complex of at least about  $10^{-8}$ ,  $10^{-9}$ ,  $10^{-10}$ ,  $10^{-11}$  or  $10^{-12}$  M.
- ~~283.~~ The isolated antibody of Claim ~~271~~ or 2, wherein said antibody is a monoclonal antibody, ~~a humanized antibody or a single chain antibody.~~

**Existing claims 29 and 30 are to be deleted.**

- ~~314.~~ The isolated antibody of Claim ~~271~~ or 2, wherein said antibody is an antibody fragment, ~~a monoclonal antibody, a single chain antibody, or an anti-idiotypic antibody.~~
- ~~325.~~ A composition of matter comprising  
(a) ~~an IL-17A/F polypeptide or complex as defined in any one of Claims 17 to 24; or~~  
(b) ~~an antagonist anti-IL-17A/F antibody as defined in any one of claims 27 to 31~~ 1 to 4;  
in combination with a carrier.
- ~~336.~~ The composition of matter of Claim ~~325~~, wherein said carrier is a pharmaceutically acceptable carrier.
- ~~347.~~ The composition of matter of Claim ~~325~~ which is useful for the treatment of an immune related disease in a mammal.

**Existing claim 35 is to be deleted.**

- ~~368.~~ The composition of matter of Claim ~~325~~, ~~wherein (b) which~~ is capable of (i) inhibiting the proliferation of T-lymphocytes in a mammal, or (ii) decreasing infiltration of inflammatory cells into a tissue of a mammal.
- ~~379.~~ The composition of matter of Claim ~~325~~ comprising a therapeutically effective amount of ~~(a) or (b)~~ the antagonist anti-IL-17A/F antibody.
- ~~3810.~~ An article of manufacture, comprising:  
a container;  
a label on said container; and

a composition of matter according to Claim 325 contained within said container, wherein label on said container indicates that said composition of matter can be used for treating an immune related disease.

**Existing claim 39 is to be deleted.**

4011. Use of an antagonist anti-IL-17A/F antibody as defined in Claim 271 or 2 in the preparation of a medicament for  
(i) ~~the treatment of an immune related disorder;~~  
(ii) ~~inhibiting the proliferation of T lymphocytes; or~~  
(iii) ~~decreasing the infiltration of inflammatory cells into a tissue in a mammal in need thereof~~ the treatment of inflammatory disease.

4112. The use according to Claim 39 or Claim 4011 wherein the immune related disorder inflammatory disease is ~~systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis, a spondyloarthropathy, systemic sclerosis, an idiopathic inflammatory myopathy, Sjögren's syndrome, systemic vasculitis, sarcoidosis, autoimmune haemolytic anemia, autoimmune thrombocytopenia, thyroiditis, diabetes mellitus, immune-mediated renal disease, a demyelinating disease of the central or peripheral nervous system, idiopathic demyelinating polyneuropathy, Guillain-Barré syndrome, a chronic inflammatory demyelinating polyneuropathy, a hepatobiliary disease, infectious or autoimmune chronic active hepatitis, primary biliary cirrhosis, granulomatous hepatitis, sclerosing cholangitis, inflammatory bowel disease, gluten-sensitive enteropathy, Whipple's disease, an autoimmune or immune-mediated skin disease, a bullous skin disease, erythema multiforme, contact dermatitis, psoriasis, an allergic disease, or asthma, allergic rhinitis, atopic dermatitis, food hypersensitivity, urticaria, an immunologic disease of the lung, eosinophilic pneumonia, idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, a transplantation associated disease, graft rejection or graft-versus-host disease.~~

13. The isolated antibody of Claim 1 or 2 for use as an antagonist of the IL-17A/F heterodimeric complex in a method of medical treatment.

**Existing claims 42 – 49 are to be deleted.**

14. An isolated antibody which specifically binds to an isolated IL-17A/F heterodimeric complex and which inhibits the activity of the IL-17A/F heterodimeric complex to induce production of IL-8 and IL-6,

wherein the isolated IL-17A/F heterodimeric complex comprises SEQ ID NO:3 and SEQ ID NO:4, without their associated signal peptides, and further comprises two interchain disulfide linkages between SEQ ID NO:3 and SEQ ID NO:4;

and wherein the antibody is for use as an antagonist of the IL-17A/F heterodimeric complex in a method of medical treatment.

15. The isolated antibody for use of Claim 14, wherein said antibody has a Kd for the IL-17A/F heterodimeric complex of at least about  $10^{-8}$ ,  $10^{-9}$ ,  $10^{-10}$ ,  $10^{-11}$  or  $10^{-12}$  M.

16. The isolated antibody for use of Claim 14 or 15, wherein said antibody is a humanized or human antibody.

17. The isolated antibody for use of Claim 14 or 15, wherein said antibody is a monoclonal antibody, which preferably has nonhuman complementarity determining region (CDR) residues and human framework region (FR) residues.
18. The isolated antibody for use of Claim 14 or 15, wherein said antibody is an antibody fragment, a monoclonal antibody, a single-chain antibody, or an anti-idiotypic antibody.
19. Use of an antagonist anti-IL-17A/F antibody as defined in Claim 14, 15 or 16 in the preparation of a medicament for antagonizing the IL-17A/F heterodimeric complex in the treatment of inflammatory disease.
20. The use according to Claim 19 wherein the inflammatory disease is rheumatoid arthritis, psoriasis, or asthma.
21. The isolated antibody for use of Claim 14, 15 or 16 wherein the method of medical treatment is a treatment of inflammatory disease.
22. The isolated antibody for use of Claim 21 wherein the inflammatory disease is rheumatoid arthritis, psoriasis, or asthma.

Key:

Single underlined and strike through indicates amendments offered on an unconditional basis

Double underlined indicates amendments offered on a conditional basis